Navigation Links
Chemokine Therapeutics Announces Preliminary Results of CTCE-9908,Phase Ib/II Clinical Trial in Late Stage Cancer Patients

eriod of four consecutive weeks (20 doses in total), with each subject receiving a dose level defined by the dose-escalation schedule. The Phase Ib/II trial includes subjects with advanced tumors refractory to the current standard of care. The trial enrolled patients at the Clinical Research Unit of both the Juravinski Cancer Center (Hamilton, Ontario, Canada) and the Sir Mortimer B. Davis - Jewish General Hospital (Montreal, Quebec, Canada).

During the dose-escalation portion of the Phase Ib/II trial, a total of ten patients were treated with CTCE-9908 with doses ranging from 0.25 to 5 mg/kg/day. Six of the patients received the expected 20 dose course of treatment. Eight of the ten patients received doses within the expected therapeutic range of 1 to 5 mg/kg/day. Among these patients, there were three with late stage ovarian cancer. Two of the three ovarian cancer patients demonstrated stable disease using the Response Evaluation Criteria in Solid Tumors (RECIST) when comparing the size of target tumors at baseline before treatment with CTCE-9908 to the assessment performed at completion of therapy. One of these patients defined as stable disease had an overall decrease tumour mass with an associated decrease of greater than 50% in CA-125 after 9 doses of CTCE-9908 while receiving no other therapy. CA-125 is an ovarian cancer biomarker that is used to monitor disease status and response to treatment.

The daily infusions at all dose levels were generally well tolerated with one subject at the 5mg/kg dose level experiencing moderate localized phlebitis that was attributed to the study drug. No serious adverse events were recorded that were attributed to the use of CTCE-9908 after 20 or more doses.

About CTCE-9908

CTCE-9908 is a peptide analog of the Chemokine SDF-1, and an antagonist of its receptor, CXCR4. SDF-1 is the only known naturally occurring chemokine that binds to CXCR4, which is present on many cancer cells. This binding proces
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:11/21/2014)... --  Wellcentive , the industry leader in end-to-end ... today being named one of the four finalists ...  Sponsored by Intel, the world leader in computing ... companies developing leading-edge technology and unique approaches to ... Wellcentive,s Mason Beard , senior vice ...
(Date:11/18/2014)... Nov. 18, 2014 Respiratory Motion and IMI ... medical device and services providers in Japan ... Respiratory Motion,s innovative respiratory depression monitor, the ExSpiron™. As ... are working together to connect the clinical community in ... history of bringing innovative medical devices and new technology ...
(Date:11/18/2014)... 18, 2014 Investor-Edge has initiated coverage ... ), Geron Corporation (NASDAQ: GERN ), Tekmira Pharmaceuticals ... GALE ), and XOMA Corporation (NASDAQ: ... accessed at: http://investor-edge.com/register . The US markets ... as the Dow Jones Industrial Average finished at 17,647.75, up ...
Breaking Medicine Technology:Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 2Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 4Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA 2Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA 3Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA 4Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA 5
(Date:11/21/2014)... The cost of diabetes care in the United States ... more than $322 billion annually, a new report shows. ... prediabetes care, which have risen 74 percent, and undiagnosed ... In 2012, excess medical costs and lost productivity ... American. That total includes $244 billion in medical costs ...
(Date:11/21/2014)... 2014 Richard Wolfe, co-founder and ... present advanced benefits administration strategies during the Game ... Leadership Summit. This Game Changer breakout session enables ... present cutting-edge solutions and best practices to top ... real-time data exchange between health and welfare benefits ...
(Date:11/21/2014)... Kansas City, Mo (PRWEB) November 21, 2014 ... has received the Get With The Guidelines®–Heart Failure ... improvement measures outlined by the American Heart Association/American ... guidelines for heart failure patients. , Get With ... that helps hospital teams provide the most up-to-date, ...
(Date:11/21/2014)... NJ (PRWEB) November 21, 2014 The ... homemade, high calorie dishes, plenty of gravy and a ... could be the best time of year to begin ... Diet Doc has uncovered the secret to losing unhealthy, ... the fattening holiday recipes. , The insight to Diet ...
(Date:11/21/2014)... Midway through the research period for the 2015 ... of Health Plans, preliminary data shows volatility in the ... is a comprehensive resource with enrollment data and contact ... 2015 edition will be available in February. ... Division, the company’s exclusive in-house research team, have identified ...
Breaking Medicine News(10 mins):Health News:Cost of Diabetes Care Keeps Climbing, Report Shows 2Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 2Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 3Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 3Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 4Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 2Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 3Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 4Health News:Data from Atlantic Information Services’s Forthcoming Directory Shows Volatility in U.S. Health Care Market 2
... , McALLEN, Texas, Dec. 3 The Ensign ... it has acquired three Texas skilled nursing facilities: the ... the 100-bed Alta Vista Rehabilitation & Healthcare in Brownsville; ... The acquisitions were effective December 1, 2009. , (Logo: ...
... , MINNEAPOLIS, Dec. 3 The American Association of Poison ... Minneapolis, Minnesota as an accredited poison control center - a ... AAPCC places the Hennepin Regional Poison Center among 58 accredited ... major accomplishment. It means we have met the national standards ...
... , NEW YORK, Dec. ... is available in its catalogue: , Point of Care ... review and analysis of the point of care (POC) diagnostics ... POC diagnostics industry , Covers federal regulation of POC ...
... , Statement by John Gay, Executive Director and ... to a new campaign launched today by the U.S. ... marketplace of "rogue" marketers selling steroids as dietary supplements, ... association representing retailers and manufacturers of dietary supplements and ...
... finds rising incidence of obesity could counter recent increases in ... health of the U.S. population has improved over the past ... but a new study suggests those gains might soon be ... level off or drop. , If current trends in both ...
... added batches now available, many more to come, NIH director ... stem cell lines have been added to the pool that ... lines will soon be made available, U.S. health officials announced ... lines approved for research funded by the U.S. National Institutes ...
Cached Medicine News:Health News:The Ensign Group Acquires Three Texas Skilled Nursing Facilities 2Health News:The Ensign Group Acquires Three Texas Skilled Nursing Facilities 3Health News:Hennepin Regional Poison Center Designated as an Accredited Poison Control Center 2Health News:Reportlinker Adds Point of Care Diagnostics 2Health News:Reportlinker Adds Point of Care Diagnostics 3Health News:Reportlinker Adds Point of Care Diagnostics 4Health News:Reportlinker Adds Point of Care Diagnostics 5Health News:Reportlinker Adds Point of Care Diagnostics 6Health News:Reportlinker Adds Point of Care Diagnostics 7Health News:Reportlinker Adds Point of Care Diagnostics 8Health News:Reportlinker Adds Point of Care Diagnostics 9Health News:Reportlinker Adds Point of Care Diagnostics 10Health News:Reportlinker Adds Point of Care Diagnostics 11Health News:Reportlinker Adds Point of Care Diagnostics 12Health News:Natural Products Association Issues Statement on New Supplement Safety Campaign 2Health News:Health Gains From Lowered Smoking Rates in Jeopardy 2Health News:Health Gains From Lowered Smoking Rates in Jeopardy 3Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 2Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 3
Large: 22 x 25 mm, 0.9 x 1.0 inches. With holes. For support of the orbital rim following enucleation. Available in methylmethacrylate....
Designed to insert eye spheres using spring loaded plunger. Polished finish. Overall length: 125 mm, 4.9 inches....
... Size: 3.0 x 7.5 x 80 ... Sponge II line designed by Harvey ... is a closed cell sponge which ... soft with rounded edges to minimize ...
... mm. Storz offers the original Scleral ... A. Lincoff, M.D. The material is ... non-toxic and non-antigenic. Implants are soft ... intrusion. These implants are packaged sterile ...
Medicine Products: